The World's First Selective-Dose Pharmaceutical Grade Medicinal Plants Inhaler
We finally may have a delivery system for medical cannabis that is effective, stable, safe and easy to use.Journal of Pain & Palliative Care Pharmacotherapy - Reviewer
No Chemical Alteration
No Added Excipients
100 Microgram Resolution
Journal of Pain & Palliative Care Pharmacotherapy – Reviewer
We finally may have a delivery system for medical cannabis that is effective, stable, safe and easy to use
The Wall Street Journal
Doctor-prescribed joints might one day become a relic of the past if cannabis technology venture Syqe Medical Ltd. has its way.
Senior government official
This is the perfect solution to all the challenges today in the cannabis field
Israeli start-up may be set to revolutionize the way cannabis is taken by patients suffering from severe pain
FastCompany: The World’s Most Innovative Companies 2017
…another step toward marijuana becoming a normal part of the drug cabinet
Teva inks trailblazing cannabis pact with Israel’s Syqe Medical
Israeli Cannabis Inhaler May Get Tested With Opium Poppy Next
Israel has high hopes for its nascent medical marijuana sector
Professor Rafael Mechoulam
…a very important advance.
A hospital version selective-dose cannabis inhaler for professional healthcare use, featuring a caregiver interface. Aimed at providing nurses and caregivers with a certified medical device for use in pain clinics, cancer centers, intensive care units and other medical institutions. The Syqe Inhaler Exo is available for hospital use in Israel.
Clinical trials are at the forefront of our strategy, providing clinical evidence and leveraging the full potential of our technology. Our recent trial demonstrated the feasibility and the first-in-class positioning of our inhaler platform. The objective of the study was to assess the potential of the Syqe Inhaler Exo in terms of pharmacokinetics, accuracy of dosing, safety, tolerability, efficacy and ease of use. This trial suggests the potential use of the Syqe Inhaler Platform, producing a Δ⁹-THC pharmacokinetic profile with low-interindividual variation of Cmax, achieving pharmaceutical standards for inhaled drugs.
Journal of Pain & Palliative Care PharmacotherapyThe Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a StudyElon Eisenberg, Miri Ogintz, and Shlomo Almog
Interindividual variability of Δ⁹-THC plasma Cmax obtained by various modes of delivery.
Δ⁹-THC plasma Cmax levels per mg administered by various modes of delivery.
Δ⁹-THC plasma levels following single-dose inhalation of 15.1 ± 0.1 mg cannabis flos
Accurately enter the therapeutic window and seamlessly maintain it.
Eytan is a former Director-General of Israel’s Ministry of Health, and the Soroka and Assuta Medical Centers. An ex-director of Clalit HMO central district, Eytan is a qualified general practitioner, and graduate of Israel’s Ben Gurion Medical School, Beer Sheva.
Perry Davidson is the Founder and CEO of Syqe Medical. An inventor of patents in various fields, including the company’s core technology, Perry was Co-founder and former CEO of Israel’s first and largest medical cannabis production company. He has more than a decade’s experience in controlled substance regulation and state implementation.
Experienced CFO of high-tech and industrial companies, including US publicly traded. TAT Technologies Ltd (NASDAQ:TATT), Aerospace and Defense, Provigent Inc., acquired by Broadcom (NASDAQ:BRCM) Semiconductors. Led significant M&A process, responsible for financials and operations. Certified Public Accountant, MBA, BA in Accounting & LLB.
James Amihood is Syqe’s General Manager. A South African by birth, James has 25 years of management experience, holding senior positions at global, Nasdaq-traded healthcare companies, managing subsidiaries and heading Business Development. James holds an MBA, B.Sc. in Chemistry, and a B.Sc. in industrial engineering.
Revital Rodovsky is Syqe’s CFO. With almost 15 years’ executive experience, Revital served as CFO for a number of tech companies in the medical device and communication spaces, successfully leading a string of mergers and acquisitions. Revital holds a certified public accountant diploma and a BA in Business Management.
Daniella Atzmony is Syqe’s chief intellectual property officer and general counsel, responsible for legal and IP issues. An advocate and patent attorney, Daniella previously worked at one of Israel’s largest patent firms, and has provided in-house IP advice to a number of start-ups. Daniella holds a PhD in Biology, and chairs Israel’s In-House IP Managers Forum.
Melina Arazy is Syqe’s VP of Clinical Affairs, responsible for all clinical and regulatory matters, and Syqe’s scientific advisory board. In the 17 years Melina has worked in the pharmaceutical and medical space, she’s held leading roles at Teva, Novartis, Merck and Lumenis. Prior to Syqe, she was VP of Clinical Affairs at Exalenz.
Benjamin Schwartz leads Syqe’s multidisciplinary R&D team. An electronics engineer by trade, he’s led a number of projects for defence companies, such as Rafael and Elbit, focusing on aviation and special forces’ technologies. Benny was one of Syqe’s first employees.
Seth Kindler is Syqe’s Chief Science Officer. A psychiatrist with more than 20 years’ experience in the biopharmaceutical sector, Seth served as Medical Director at Pharmos, and consulted for several cannabis-based startups. Seth is a former Deputy Director of the Sheba Hospital’s Psychiatric Ward, and headed the Israeli Army’s PTSD Clinical Research Program.
Elon Eisenberg heads up Syqe’s Scientific Advisory Board for Pain Management, and sits on the Executive Board of the European Pain Federation. Elon leads the Pain Research Unit at Rambam Medical Center. He’s also an associate professor of Neurology & Pain at the Technion.
Brian Cooper is a member of Syqe’s Board of Directors, and co-founder investor. Brian is the founder and former CFO of retail software company, Retalix, which was sold to NCR for $650m. He’s an active Angel and early-stage investor in a number of IT and Life Science companies.